Most Read Articles
Pearl Toh, 08 Jan 2021
Combining the anti-PD-1 antibody sintilimab and a bevacizumab biosimilar significantly improves survival compared with the standard treatment of sorafenib in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma (HCC), according to the ORIENT-32 study presented at ESMO Asia 2020.
Dr Margaret Shi, 15 Jan 2021

Cancer patients at are an increased risk of severe coronavirus disease 2019 (COVID-19) and should be positioned at high priority for vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) regardless of age, according to statements issued by the European Society for Medical Oncology (ESMO).

Adding metformin to TKI may be detrimental to nondiabetic patients with EGFR-positive NSCLC

19 Jan 2020

The concurrent use of metformin with the tyrosine kinase inhibitor (TKI) gefitinib does more harm than good, resulting in significantly worse outcomes and increasing the risk of diarrhoea in nondiabetic patients with nonsmall cell lung cancer (NSCLC) harbouring EFGR mutation, according to data from a phase II trial.

A total of 224 nondiabetic patients (median age, 59.6 years; 75.0 percent nonsmokers) with treatment-naïve stage IIIB–IV EGFR-mutated NSCLC were randomized to receive gefitinib plus either metformin (n=112) or placebo (n=112). The majority of patients had a stage IV disease, with adenocarcinoma being the predominant pathologic type.

The median follow-up duration was 19.15 months. Progression-free survival (PFS) rate at 1 year was similar in the metformin and placebo groups (41.2 percent vs 42.9 percent; p=0.6268), as was overall response rate (66 percent vs 66.7 percent, respectively).

However, the metformin-treated patients had slightly shorter PFS (median, 10.3 vs 11.4 months) and overall survival (median, 22.0 vs 27.5 months). In subgroup analysis, including patients with elevated levels of IL6, PFS did not significantly differ between the metformin and placebo groups.

In terms of safety, combining metformin with gefitinib resulted in a markedly higher incidence of diarrhoea compared with the control arm (78.38 percent vs 43.24 percent).

The findings do not support the concurrent use of metformin with first-line TKI therapy in nondiabetic patients with EGFR-mutated NSCLC, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 08 Jan 2021
Combining the anti-PD-1 antibody sintilimab and a bevacizumab biosimilar significantly improves survival compared with the standard treatment of sorafenib in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma (HCC), according to the ORIENT-32 study presented at ESMO Asia 2020.
Dr Margaret Shi, 15 Jan 2021

Cancer patients at are an increased risk of severe coronavirus disease 2019 (COVID-19) and should be positioned at high priority for vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) regardless of age, according to statements issued by the European Society for Medical Oncology (ESMO).